Quick Answer
GALECTIN THERAPEUTICS INC reported R&D Expense of $14.29 million for fiscal year 2025.
GALECTIN THERAPEUTICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $14.29M | -60.9% |
| 2024 | $36.57M | +13.8% |
| 2023 | $32.13M | +1.2% |
| 2022 | $31.74M | +33.2% |
| 2021 | $23.82M | +32.5% |
| 2020 | $17.98M | +140.7% |
| 2019 | $7.47M | +15.4% |
| 2018 | $6.47M | -44.8% |
| 2017 | $11.72M | -23.5% |
| 2016 | $15.32M | +16.9% |
| 2015 | $13.11M | +55.7% |
| 2014 | $8.43M | +48.1% |
| 2013 | $5.69M | +25.6% |
| 2012 | $4.53M | +27.4% |
| 2011 | $3.55M | +233.2% |
| 2010 | $1.07M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.61M | -65.6% | -19.9% |
| June 30, 2025 | $3.26M | -66.8% | -49.7% |
| March 31, 2025 | $6.49M | -19.5% | -14.6% |
| September 30, 2024 | $7.59M | -1.8% | -22.6% |
| June 30, 2024 | $9.81M | +33.1% | +21.8% |
| March 31, 2024 | $8.05M | -8.5% | +4.2% |
| September 30, 2023 | $7.73M | +17.2% | +4.9% |
| June 30, 2023 | $7.37M | -8.7% | -16.2% |
- GALECTIN THERAPEUTICS INC showed a decrease of -60.9% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, GALECTIN THERAPEUTICS INC’s r&d expense has grown by 1240.5% (from $1.07 million to $14.29 million).
- The most recent figure is from GALECTIN THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: